What Latest Treatment Options for Gastric Cancer Could Promote Patient Outcomes Globally?

Over the past few years, gastric cancer, also known as stomach cancer, has become one of the most significant types of cancer. Though this kind of cancer is highly malignant and fast-growing, it is still underrated. The major cause behind the severity of stomach cancer is its aggressive tumor biology. However, the advancements in medical research and technology have paved the way for exciting developments in the diagnosis and treatment of this disease. 

Recently, according to a report published by Research Dive, the increasing investment in research & development for gastric cancer treatments such as the development of more advanced diagnostic tools and screening techniques for the early detection of gastric cancer is expected to fortify the growth of the global gastric cancer market. The market is anticipated to generate a revenue of $10,737.00 million and rise at a striking CAGR of 17.9% over the estimated period from 2022 to 2031. The major players of the market include Mylan N.V., Novartis AG, Eli Lilly and Company, Pfizer, Inc., and many more. 

Latest Treatment Options for Gastric Cancer

The latest trends and promising developments in the management of gastric cancer hold the potential to improve patient outcomes, enhance survival rates, and provide new hope for individuals affected by these challenging conditions. Some of them are discussed below:

• Precision Medicine and Molecular Profiling: By analyzing the genetic and molecular characteristics of a patient’s tumor, doctors can identify specific alterations that drive cancer growth. This information allows for personalized treatment approaches tailored to the individual’s unique tumor biology.
  
  Molecular profiling enables the identification of potential therapeutic targets and helps guide treatment decisions, including the selection of targeted therapies or participation in clinical trials. Such an approach has improved patient outcomes and is gradually transforming the landscape of gastric cancer treatment. 
   
• Immunotherapy Advancements: Immunotherapy has revolutionized cancer treatment in recent years, and gastric cancer is no exception. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have shown remarkable efficiency in a subset of patients with advanced gastric cancer. These medications unleash the power of the patient’s immune system by blocking molecules that inhibit immune cells from recognizing and attacking cancer cells.
  
  The use of immunotherapy has extended survival rates and imposed quality of life for patients who previously had limited treatment options.  Ongoing research focuses on identifying predictive biomarkers to better select patients who are most likely to benefit from immunotherapy, further optimizing its use in gastric cancer treatment. 
   
• Targeted Therapies: These therapies aim to specifically inhibit molecules or pathways that are crucial for tumor growth and survival. For instance, trastuzumab is a targeted therapy approved for gastric cancer patients who have tumors with overexpressed HER2 receptors. Additionally, ramucirumab targets the angiogenic pathway involved in tumor development. 
  
  Targeted therapies offer a more precise and effective treatment option while minimizing harm to healthy cells. Ongoing research efforts continue to uncover additional targets and develop novel targeted therapies that show potential improving outcomes for gastric cancer patients.
   
• Minimally Invasive Surgical Techniques: Laparoscopic and robotic-assisted surgeries have gained popularity as they offer several advantages over traditional open surgery. These techniques involve similar incisions, resulting in reduced postoperative pain, shorter hospital stays, and faster recovery times. Robotic-assisted surgery provides enhanced precision and dexterity for surgeons.
  
  Minimally invasive procedures not only improve patient comfort and quality of life but also reduce the risk of complications. As these techniques continue to evolve, they hold the potential to become the standard of care for gastric cancer surgeries. 

Why are Men at Higher Risk of Having Gastric Cancer?

According to research, it is found that gastric cancer is prevalent in men due to the hormonal difference. The estrogen hormone present in females protects them against inflammation and reduces their possibility of getting diagnosed with gastric or stomach cancer. However, the advancement in medical science is expected to help men to avoid the risk of such types of cancer and overcome the disease more efficiently.

About the Author(s)

Princy A. J

Princy holds a bachelor’s degree in Civil Engineering from the prestigious Tamil Nadu Dr. M.G.R. University at Chennai, India. After a successful academic record, she pursued her passion for writing. A thorough professional and enthusiastic writer, she enjoys writing on various categories and advancements in the global industries. She plays an instrumental role in writing about current updates, news, blogs, and trends.